✦ LIBER ✦

A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: Preliminary results of a phase I study

✍ Scribed by Scott E. Plevy; Bruce A. Salzberg; Miguel Regueiro; William Sandborn; Stephen B. Hanauer; Stephan R. Targan; Lloyd Mayer; Ian B. Walters

Book ID: 119426894
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 180 KB
Volume: 124
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(03)80033-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II Multicenter Study of Visilizu

A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease

✍ Paul A. Carpenter; James Lowder; Laura Johnston; Haydar Frangoul; Hanna Khoury; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 256 KB

Ocrelizumab, a humanized anti-CD20 monoc

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

✍ Mark C. Genovese; Jeffrey L. Kaine; Mitchell B. Lowenstein; José Del Giudice; An 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

MTRX1011A, a humanized anti-CD4 monoclon

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

✍ Scheerens, Heleen; Su, Zheng; Irving, Bryan; Townsend, Michael J; Zheng, Yanan; 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 260 KB

P-974 Treatment of non-small cell lung c

P-974 Treatment of non-small cell lung cancer (NSCLC) patients withthe trifunctional bispecific antibody catumaxomab (removab®) (anti-EpCAM × anti-CD3: Results of a phase I study

✍ Sebastian, M.; Schmittel, A.; Friccius-Quecke, H.; Kanniess, F.; Wiewrodt, R.; L 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

Ofatumumab, a human anti-CD20 monoclonal

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

✍ Mikkel Østergaard; Bo Baslund; William Rigby; Bernadette Rojkovich; Christian Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 2 views